Match!
Ryuzo Ueda
Aichi Medical University
636Publications
79H-index
23.1kCitations
Publications 636
Newest
#1Yuma Sakamoto (Nagoya City University)H-Index: 2
#2Keiichiro Fujii (Nagoya City University)H-Index: 1
Last.Hiroshi Inagaki (Nagoya City University)H-Index: 26
view all 12 authors...
CCR4 is expressed on tumor cells of most patients with adult T-cell leukemia/lymphoma (ATL). Gain-of-function mutations of the CCR4 gene in ATL patients may be associated with alterations at the carboxyl terminus, a finding which led to a high efficacy anti-CCR4 antibody, mogamulizumab. Only a few studies have reported CCR4 protein expression and genomic CCR4 mutations in non-ATL T/NK-cell lymphomas. Furthermore, an association between CCR4 protein expression, genomic CCR4 mutations, and transcr...
Source
#1Masahito WatanabeH-Index: 4
#2Kent KanaoH-Index: 14
Last.Makoto SumitomoH-Index: 27
view all 15 authors...
Source
#1Keiko Maekawa (Doshisha Women's College of Liberal Arts)H-Index: 25
#2Masaki Ri (Nagoya City University)H-Index: 17
Last.Shinsuke Iida (Nagoya City University)H-Index: 38
view all 9 authors...
Source
#1Nobuhiro Asai (Aichi Medical University)H-Index: 7
#2Akihito Kubo (Aichi Medical University)H-Index: 20
Last.Etsuro Yamaguchi (Aichi Medical University)H-Index: 28
view all 8 authors...
AbstractTo clarify the prognostic impact of tumor-infiltrating effector regulatory T cells (eTregs) in non-small cell lung cancer (NSCLC), eTregs were evaluated by immunohistochemical detection of CCR4 and Foxp3 in 108 consecutive surgical NSCLC tumors. Multivariate analysis showed that a high ratio of CCR4+ eTregs to total Tregs (≥40%) was the only independent risk factor for relapse-free survival (odds ratio [OR]: 6.54, 95% confidence interval: 1.67–25.7, p = .007) and overall survival (OR: 3....
2 CitationsSource
#1Takashi Ishida (Nagoya City University)H-Index: 40
#2Tatsuro JoH-Index: 8
Last.Ryuzo Ueda (Aichi Medical University)H-Index: 79
view all 23 authors...
4 CitationsSource
#1Dai MaruyamaH-Index: 18
#2Kunihiro TsukasakiH-Index: 41
Last.Kensei TobinaiH-Index: 45
view all 21 authors...
Peripheral T cell lymphomas are an aggressive group of non-Hodgkin lymphomas with poor outcomes for most subtypes and no accepted standard of care for relapsed patients. This study evaluated the efficacy and safety of forodesine, a novel purine nucleoside phosphorylase inhibitor, in patients with relapsed peripheral T cell lymphomas. Patients with histologically confirmed disease, progression after ≥ 1 prior treatment, and an objective response to last treatment received oral forodesine 300 mg t...
2 CitationsSource
#1Akira SatouH-Index: 7
#2Shogo BannoH-Index: 14
Last.Toyonori TsuzukiH-Index: 28
view all 12 authors...
2 CitationsSource
#1Shiori Kinoshita (Nagoya City University)H-Index: 4
#2Takashi Ishida (Nagoya City University)H-Index: 40
Last.Shinsuke Iida (Nagoya City University)H-Index: 38
view all 17 authors...
BAY 1143572 is a highly selective inhibitor of cyclin-dependent kinase 9/positive transcription elongation factor b. It has entered phase I clinical studies. Here, we have assessed the utility of BAY 1143572 for treating natural killer (NK) cell leukemias/lymphomas that have a poor prognosis, namely extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia, in a preclinical mouse model in vivo as well as in tissue culture models in vitro. Seven NK cell leukemia/lymphoma lines and...
Source
#1Dai MaruyamaH-Index: 18
#2Kunihiro TsukasakiH-Index: 41
Last.Kensei TobinaiH-Index: 45
view all 21 authors...
Source
#1Shohei Mizuno (Aichi Medical University)H-Index: 8
#2Ichiro Hanamura (Aichi Medical University)H-Index: 16
Last.Akiyoshi Takami (Aichi Medical University)H-Index: 26
view all 21 authors...
Source
12345678910